US FDA issues warning letter to GlaxoSmithKline

By: Pharma News | Views: 2417 | Date: 09-Apr-2014

US FDA has issued a warning letter to GlaxoSmithKline for alleged manufacturing deficiencies at the company’s manufacturing subsidiary in Cork, Ireland. The subsidiary, SmithKline Beecham (Cork) Ltd., is a manufacturer of active pharmaceutical ingredients (API) for GlaxoSmithKline (GSK).


US FDA issues warning letter to GlaxoSmithKline


GlaxoSmithKline

US FDA has issued a warning letter to GlaxoSmithKline for alleged manufacturing deficiencies at the company’s manufacturing subsidiary in Cork, Ireland. The subsidiary, SmithKline Beecham (Cork) Ltd., is a manufacturer of active pharmaceutical ingredients (API) for GlaxoSmithKline (GSK).

FDA inspected the manufacturing facility in October 2013 and identified the deviations from current good manufacturing practice (cGMP) for manufacturer of active pharmaceutical ingredient. FDA observed that the company failed to fully investigate critical deviations within the manufacturing processes. The company found out that batches used in manufacturing process were contaminated with material from your pharmaceutical waste tank, which contained APIs, intermediates, and solvents.

The company also failed to investigate and document the out of specification results and to demonstrate that your manufacturing process can reproducibly manufacture an API meeting its predetermined quality attributes. The company’s validation protocol states that a minimum of three consecutive pre-nominated process performance qualification (PPQ) batches were to be produced to demonstrate initial process validation. However, the company was unable to produce three consecutive successful batches during the production of multiple batches and therefore re-nominated the PPQ batches on two different occasions.

After this warning letter GlaxoSmithKline has recalled some batches of its antidepressants Paxil and Seroxat because the active ingredient used to make them might have been contaminated with a solvent from a pharmaceutical waste tank. The company is voluntarily withdrawing batches of the drug involved at wholesale level. The company has conducted a risk assessment of the active ingredient used in manufacturing of these drugs and found it safe for use in the manufacturing of the anti-depressants.

Previous Page Next Page

People Searching On This Page:
  • august 2013 and it was clear usfda zydus worning latter
  • how to handle out of specification in pharma us fda how to handle out of specification in pharma us fda how to handle out of specification in pharma usafda

Related Pages


Modi's industry conference in US to attract pharma, IT players

Modi's industry conference in US to attract pharma, IT players

News
Date:
02-Sep-2014  Views: 2303

Prime Minister Narendra Modi will address Indian and American industry through video conferencing during his visit to the USlater this month. The inte ...
Zydus Cadila Gets USFDA Nod for Kidney Stones Tablets

Zydus Cadila Gets USFDA Nod for Kidney Stones Tablets

News | FDA
Date:
14-Aug-2014  Views: 1848

Drug firm Zydus Cadila has received the final approval from the US health regulator to market Potassium Citrate ER tablets used in prevention of kidne ...
USFDA issues warning letter for Wockhardts Waluj plant

USFDA issues warning letter for Wockhardts Waluj plant

News | FDA
Date:
08-Aug-2013  Views: 1265

Last week, the UK Medicines and Healthcare Products Regulatory Agency (MHRA) had issued a precautionary recall for sixteen medicines manufactured by W ...
US FDA trusts Indian GMP

US FDA trusts Indian GMP

News | FDA
Date:
07-Aug-2013  Views: 1603

The United States Food and Drug Administration (USFDA), which is considered to be the most stringent authority Indian drug makers, have been following ...
Use & Abuse of Pain Killers : Focus on Methadone

Use & Abuse of Pain Killers : Focus on Methadone

Articles | Clinical Research | Clinical Case Study
Date:
27-Jul-2013  Views: 1516

Prescription painkiller overdoses were responsible for more than 15,500 deaths in 2009. While all prescription painkillers have contributed to an incr ...
Post Your Comments (No Login Require)
Name : (required)
Email : (required)
Website :

Comment : (required)

52  + 9 =     
Comments
People Searched About:
August 2013 And It Was Clear Usfda Zydus Worning Latter   |   How To Handle Out Of Specification In Pharma Us Fda How To Handle Out Of Specification In Pharma Us Fda How To Handle Out Of Specification In Pharma Usafda   |  
Google : 69 times | Yahoo : 52 times | Bing : 129 times |